{"62745":{"#nid":"62745","#data":{"type":"news","title":"Researchers Develop Oral Delivery System to Treat Inflammatory BD","body":[{"value":"\u003Cp\u003EResearchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases. Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but how to deliver them into targeted cells in a living organism has been an obstacle.\n\u003C\/p\u003E\n\u003Cp\u003EIn the Oct. 10 advance online edition of the journal Nature Materials, researchers describe how they encapsulated short pieces of RNA into engineered particles called thioketal nanoparticles and orally delivered the genetic material directly to the inflamed intestines of animals. The research was sponsored by the National Science Foundation and National Institutes of Health.\n\u003C\/p\u003E\n\u003Cp\u003E\u0022The thioketal nanoparticles we designed are stable in both acids and bases and only break open to release the pieces of RNA in the presence of reactive oxygen species, which are found in and around inflamed tissue in the gastrointestinal tract of individuals with inflammatory bowel diseases,\u0022 said Niren Murthy, an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.\n\u003C\/p\u003E\n\u003Cp\u003EThis work was done in collaboration with Emory University Division of Digestive Diseases professor Shanthi Sitaraman, associate professor Didier Merlin and postdoctoral fellow Guillaume Dalmasso.\n\u003C\/p\u003E\n\u003Cp\u003EThe thioketal nanoparticles protect the small interfering RNAs (siRNAs) from the harsh environment of the gastrointestinal tract and target them directly to the inflamed intestinal tissues. This localized approach is necessary because siRNAs can cause major side-effects if injected systemically.\n\u003C\/p\u003E\n\u003Cp\u003EIn the paper, the thioketal nanoparticles were formulated from a new polymer - poly-(1,4-phenyleneacetone dimethylene thioketal) (PPADT) - and engineered to have a diameter of approximately 600 nanometers for optimal oral delivery.\n\u003C\/p\u003E\n\u003Cp\u003EFor their experiments, the researchers used a mouse model of ulcerative colitis \u2014 a debilitating inflammatory bowel disease in which the digestive tract becomes inflamed, causing severe diarrhea and abdominal pain that can lead to life-threatening complications.\n\u003C\/p\u003E\n\u003Cp\u003EThe researchers orally administered thioketal nanoparticles loaded with siRNA that inhibits an inflammation-promoting cytokine called tumor necrosis factor \u2013 alpha (TNF-\u03b1). The nanoparticles traveled directly to the mouse colons where reactive oxygen species were being produced in excess and decreased the cytokine production levels there.\n\u003C\/p\u003E\n\u003Cp\u003ETissue samples from the colons treated with siRNA delivered by these thioketal nanoparticles exhibited intact epitheliums, well-defined fingerlike \u0022crypt\u0022 structures and lower levels of inflammation \u2014 signs that the colon was protected against ulcerative colitis.\n\u003C\/p\u003E\n\u003Cp\u003E\u0022Since ulcerative colitis is restricted to the colon, these results confirm that the siRNA-loaded thioketal nanoparticles remain stable in non-inflamed regions of the gastrointestinal tract while targeting siRNA to inflamed intestinal tissues,\u0022 explained the paper\u0027s lead author Scott Wilson, a graduate student in the Georgia Tech School of Chemical and Biomolecular Engineering.\n\u003C\/p\u003E\n\u003Cp\u003EThe paper showed that thioketal nanoparticles have the chemical and physical properties needed to overcome the obstacles of gastrointestinal fluids, intestinal mucosa and cellular barriers to provide therapy to inflamed intestinal tissues, he added.\n\u003C\/p\u003E\n\u003Cp\u003EThe researchers are currently working on increasing the degradation rate of the nanoparticles and enhancing their reactivity with reactive oxygen species. The team also plans to conduct a biodistribution study to detail how the nanoparticles travel through the body.\n\u003C\/p\u003E\n\u003Cp\u003E\u0022Polymer toxicity is something we\u0027ll have to investigate further, but during this study we discovered that thioketal nanoparticles loaded with siRNA have a cell toxicity profile similar to nanoparticles formulated from the FDA-approved material poly(lactic-co-glycolic acid) (PLGA),\u0022 added Murthy.\n\u003C\/p\u003E\n\u003Cp\u003EIn the future, thioketal nanoparticles may become a significant player in the treatment of numerous gastrointestinal diseases linked to intestinal inflammation, including gastrointestinal cancers, inflammatory bowel diseases and viral infections, according to Murthy.\n\u003C\/p\u003E\n\u003Cp\u003EThis project is supported by the National Science Foundation (NSF) (Award Nos. EEC-9731643 and NSF Career BES-0546962) and the National Institutes of Health (NIH) (Award Nos. UO1 HL80711-01, R21 EB006418, RO1 HL096796-01, RO1 DK071594, R01 DK064711 and T32 GM08433). The content is solely the responsibility of the principal investigator and does not necessarily represent the official views of the NSF or NIH.\n\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"Researchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases. Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but how to deliver them into targeted cells in a living organism has been an obstacle.","format":"limited_html"}],"field_summary_sentence":[{"value":"Researchers Develop Oral Delivery System to Treat Inflammatory B"}],"uid":"27349","created_gmt":"2010-10-11 00:00:00","changed_gmt":"2016-10-08 03:07:46","author":"Floyd Wood","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2010-10-10T00:00:00-04:00","iso_date":"2010-10-10T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"}],"categories":[{"id":"129","name":"Institute and Campus"},{"id":"141","name":"Chemistry and Chemical Engineering"},{"id":"134","name":"Student and Faculty"},{"id":"145","name":"Engineering"},{"id":"149","name":"Nanotechnology and Nanoscience"},{"id":"135","name":"Research"}],"keywords":[{"id":"109","name":"Georgia Tech"},{"id":"248","name":"IBB"},{"id":"9518","name":"Nature Materials"},{"id":"2076","name":"NIH"},{"id":"363","name":"NSF"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cstrong\u003EAbby Vogel Robinson\u003C\/strong\u003E\u003Cbr \/\u003EResearch News and Publications\u003Cbr \/\u003E\u003Ca href=\u0022http:\/\/www.gatech.edu\/contact\/index.html?id=avogel6\u0022\u003EContact Abby Vogel Robinson\u003C\/a\u003E\u003Cbr \/\u003E\u003Cstrong\u003E404-385-3364\u003C\/strong\u003E","format":"limited_html"}],"email":["abby@innovate.gatech.edu"],"slides":[],"orientation":[],"userdata":""}}}